miR-378a-3p sensitizes ovarian cancer cells to cisplatin through targeting MAPK1/GRB2
In conclusion, miR-378a-3p enhanced the sensitivity of ovarian cancer cells to cisplatin through targeting MAPK1 and GRB2.Graphical abstract
Source: Biomedicine and Pharmacotherapy - Category: Drugs & Pharmacology Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Drugs & Pharmacology | Ovarian Cancer | Ovaries